1992
DOI: 10.1097/00000658-199210000-00010
|View full text |Cite
|
Sign up to set email alerts
|

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

Abstract: A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

4
161
1
1

Year Published

1993
1993
2004
2004

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 364 publications
(167 citation statements)
references
References 33 publications
4
161
1
1
Order By: Relevance
“…12 There are now several reports of allogeneic vaccine efficacy in animal models. [13][14][15][16][17][18] Morton and colleagues 19 have transferred this strategy to the clinic using unmodified allogeneic cells. However, early reports of allogeneic vaccines modified to secrete IL-2 have reported a limited response.…”
Section: Introductionmentioning
confidence: 99%
“…12 There are now several reports of allogeneic vaccine efficacy in animal models. [13][14][15][16][17][18] Morton and colleagues 19 have transferred this strategy to the clinic using unmodified allogeneic cells. However, early reports of allogeneic vaccines modified to secrete IL-2 have reported a limited response.…”
Section: Introductionmentioning
confidence: 99%
“…5 Cancer vaccination may have more prophylactic benefits such as after the surgical removal of melanoma or when tumors are in the early stages of progression (subclinical disease). 21 In general, melanoma patients with AJCC II (local) or III (local regional) level disease will undergo surgical treatment to be disease free. However, the major problem that arises is disease recurrence and who will recur.…”
Section: Discussionmentioning
confidence: 99%
“…Such an approach has also shown some responses against melanoma in the clinic [14]. Perhaps allogeneic vaccination can enhance the immunogenicity of tumourassociated antigens [15] and possibly induce a graft vs tumour-like response, which may explain reports of regression of concurrent solid tumours in patients with haematological malignancy who received bone-marrow transplants [16,17].…”
Section: Introductionmentioning
confidence: 99%